Changes in cancer incidence and stage during the COVID-19 pandemic in 2020-2021 in the Nordic countries.

IF 2.7 3区 医学 Q3 ONCOLOGY
Anna Johansson, Anna Skog, Tom Børge Johannesen, Tor Åge Myklebust, Simon M Kønig, Charlotte Wessel Skovlund, Lina Steinrud Mørch, Søren Friis, Marnar Fríðheim Kristiansen, David Pettersson, Eva María Gudmundsdóttir, Nanna Margrét Kristinsdóttir, Helgi Birgisson, Sandra Irenaeus, Johan Ahlgren, Mats Lambe, Elli Hirvonen, Janne Pitkäniemi, Giske Ursin
{"title":"Changes in cancer incidence and stage during the COVID-19 pandemic in 2020-2021 in the Nordic countries.","authors":"Anna Johansson, Anna Skog, Tom Børge Johannesen, Tor Åge Myklebust, Simon M Kønig, Charlotte Wessel Skovlund, Lina Steinrud Mørch, Søren Friis, Marnar Fríðheim Kristiansen, David Pettersson, Eva María Gudmundsdóttir, Nanna Margrét Kristinsdóttir, Helgi Birgisson, Sandra Irenaeus, Johan Ahlgren, Mats Lambe, Elli Hirvonen, Janne Pitkäniemi, Giske Ursin","doi":"10.2340/1651-226X.2025.42079","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>The COVID-19 pandemic impacted substantially on cancer healthcare, including the temporary suspension of screening activities. We compared cancer incidence rates and stage during 2020-2021 to pre-pandemic rates in the Nordic countries.</p><p><strong>Material and methods: </strong>Using data from the national cancer registries in Denmark, Finland, Iceland, Norway, and Sweden, we estimated age-, sex-, and period-adjusted incidence rate ratios, expressed as relative percentage change (%) with 95% confidence intervals (CIs), comparing rates in 2020-2021 to those in 2017-2019 (pre-pandemic).</p><p><strong>Results: </strong>In 2020-2021, 340,675 cancer cases were diagnosed. The incidence rates declined during the first pandemic wave (Q2 2020), ranging from -21.7% [95% CI: -23.3%; -20.2%] (Sweden) to -7.9% [-17.7%; 3.0%] (Iceland). Incidence rates also declined in the second pandemic wave (Q1 2021), ranging from -8.6% [-10.2%; -6.9%] (Sweden) to -2.3% [-4.6%; 0.1%] (Norway), and in Sweden also by -3.1% [-4.8%; -1.3%] in the third pandemic wave (Q4 2021). Stage I breast cancer incidence declined during 2020 in Denmark/Norway/Sweden, with some catch-up in stage II incidence in 2021. Prostate cancer rates declined in Denmark/Finland/Norway/Sweden during 2020-2021, while melanoma rates declined in Finland in 2020. During 2020, colon cancer rates declined in Denmark and Iceland, while rectal cancer rates declined in Denmark, and lung and kidney cancer rates declined in Norway.</p><p><strong>Interpretation: </strong>During 2020-2021, cancer incidence rates declined across the Nordic countries with the largest declines in Sweden. During the third pandemic wave, the incidence rates were mostly similar to pre-pandemic rates. Changes in cancer stage may reflect reduced screening activities.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"257-266"},"PeriodicalIF":2.7000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833327/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Oncologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2340/1651-226X.2025.42079","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose: The COVID-19 pandemic impacted substantially on cancer healthcare, including the temporary suspension of screening activities. We compared cancer incidence rates and stage during 2020-2021 to pre-pandemic rates in the Nordic countries.

Material and methods: Using data from the national cancer registries in Denmark, Finland, Iceland, Norway, and Sweden, we estimated age-, sex-, and period-adjusted incidence rate ratios, expressed as relative percentage change (%) with 95% confidence intervals (CIs), comparing rates in 2020-2021 to those in 2017-2019 (pre-pandemic).

Results: In 2020-2021, 340,675 cancer cases were diagnosed. The incidence rates declined during the first pandemic wave (Q2 2020), ranging from -21.7% [95% CI: -23.3%; -20.2%] (Sweden) to -7.9% [-17.7%; 3.0%] (Iceland). Incidence rates also declined in the second pandemic wave (Q1 2021), ranging from -8.6% [-10.2%; -6.9%] (Sweden) to -2.3% [-4.6%; 0.1%] (Norway), and in Sweden also by -3.1% [-4.8%; -1.3%] in the third pandemic wave (Q4 2021). Stage I breast cancer incidence declined during 2020 in Denmark/Norway/Sweden, with some catch-up in stage II incidence in 2021. Prostate cancer rates declined in Denmark/Finland/Norway/Sweden during 2020-2021, while melanoma rates declined in Finland in 2020. During 2020, colon cancer rates declined in Denmark and Iceland, while rectal cancer rates declined in Denmark, and lung and kidney cancer rates declined in Norway.

Interpretation: During 2020-2021, cancer incidence rates declined across the Nordic countries with the largest declines in Sweden. During the third pandemic wave, the incidence rates were mostly similar to pre-pandemic rates. Changes in cancer stage may reflect reduced screening activities.

2020-2021年北欧国家2019冠状病毒病大流行期间癌症发病率和分期的变化
背景和目的:COVID-19大流行对癌症医疗保健产生了重大影响,包括暂停筛查活动。我们将2020-2021年期间北欧国家的癌症发病率和分期与大流行前的发病率进行了比较。材料和方法:使用来自丹麦、芬兰、冰岛、挪威和瑞典国家癌症登记处的数据,我们估计了年龄、性别和时期调整的发病率比,以相对百分比变化(%)表示,95%置信区间(ci),将2020-2021年的发病率与2017-2019年(大流行前)的发病率进行比较。结果:2020-2021年确诊癌症病例340675例。发病率在第一波大流行期间(2020年第二季度)下降,范围从-21.7%[95%置信区间:-23.3%;-20.2%](瑞典)至-7.9% [-17.7%;3.0%)(冰岛)。第二波大流行(2021年第一季度)的发病率也有所下降,从-8.6% [-10.2%;-6.9%[瑞典]至-2.3% [-4.6%;0.1%](挪威),瑞典也是-3.1% [-4.8%;-1.3%]在第三波大流行(2021年第四季度)。2020年丹麦/挪威/瑞典I期乳腺癌发病率下降,2021年II期发病率有所回升。2020-2021年期间,丹麦/芬兰/挪威/瑞典的前列腺癌发病率下降,而芬兰的黑色素瘤发病率在2020年下降。2020年期间,丹麦和冰岛的结肠癌发病率下降,丹麦的直肠癌发病率下降,挪威的肺癌和肾癌发病率下降。解释:2020-2021年期间,北欧国家的癌症发病率下降,其中瑞典下降幅度最大。在第三波大流行期间,发病率基本上与大流行前的发病率相似。癌症分期的变化可能反映了筛查活动的减少。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Oncologica
Acta Oncologica 医学-肿瘤学
CiteScore
4.30
自引率
3.20%
发文量
301
审稿时长
3 months
期刊介绍: Acta Oncologica is a journal for the clinical oncologist and accepts articles within all fields of clinical cancer research. Articles on tumour pathology, experimental oncology, radiobiology, cancer epidemiology and medical radio physics are also welcome, especially if they have a clinical aim or interest. Scientific articles on cancer nursing and psychological or social aspects of cancer are also welcomed. Extensive material may be published as Supplements, for which special conditions apply.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信